Filtered By:
Specialty: Allergy & Immunology
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 67 results found since Jan 2013.
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years
CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.PMID:37541822 | DOI:10.1016/j.vaccine.2023.07.025
Source: Vaccine - August 4, 2023 Category: Allergy & Immunology Authors: David Singer Ahmed Salem Nikita Stempniewicz Siyu Ma Sara Poston Desmond Curran Source Type: research
Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan
CONCLUSIONS: Varicella incidence and healthcare resource use were largely affected by the routine immunization program and infection prevention measures against COVID-19, while these impacts on herpes zoster were relatively small. Our study indicates that immunization and infection prevention measures largely changed pediatric infectious disease practices.PMID:37400282 | DOI:10.1016/j.vaccine.2023.06.054
Source: Vaccine - July 3, 2023 Category: Allergy & Immunology Authors: Kazuhiro Uda Yusuke Okubo Mitsuru Tsuge Hirokazu Tsukahara Isao Miyairi Source Type: research
Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine
CONCLUSIONS: This large post-licensure study did not identify evidence of safety concerns for HepB-CpG compared to HepB-alum for immune-mediated diseases, HZ, or anaphylaxis.PMID:37308363 | DOI:10.1016/j.vaccine.2023.06.004
Source: Vaccine - June 12, 2023 Category: Allergy & Immunology Authors: Bradley Ackerson Lina S Sy Jeff Slezak Lei Qian Kristi Reynolds Runxin Huang Zendi Solano William Towner Sijia Qiu Sarah R Simmons Steven J Jacobsen Katia J Bruxvoort Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" Int. Immunopharmacol. 101(Part B) (2021) 108216
Int Immunopharmacol. 2023 May 5:110260. doi: 10.1016/j.intimp.2023.110260. Online ahead of print.NO ABSTRACTPMID:37150708 | DOI:10.1016/j.intimp.2023.110260
Source: International Immunopharmacology - May 7, 2023 Category: Allergy & Immunology Authors: Lei He Bo Sun Yingnan Guo Kunming Yan Dawei Liu Yang Zang Chunlai Jiang Yong Zhang Wei Kong Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of varicella-zoster virus immunoglobulin G antibodies in fingerstick blood
J Immunol Methods. 2023 Jan 21;514:113429. doi: 10.1016/j.jim.2023.113429. Online ahead of print.ABSTRACTVaricella zoster virus (VZV) causes childhood chickenpox, becomes latent in sensory ganglia and reactivates years later to cause shingles (Zoster) and postherpetic neuralgia in the elderly and immunosuppressed individuals. Serologic IgG tests can be used to determine if a person has antibodies to VZV from past varicella infection or had received varicella or zoster (shingles) vaccination. Commercial enzyme-linked immunosorbent assays (ELISAs) are currently used for the detection of VZV IgG antibodies in patient serum sa...
Source: Journal of Immunological Methods - January 23, 2023 Category: Allergy & Immunology Authors: Nicholas Vafai Kevin Self Bret Sheffield Sally Hojvat Aubrey Kusi-Appiah Patrick Vaughan Elliot Cowan Abbas Vafai Source Type: research
